Coding & Reimbursement
for the 2021-2022 Season

Influenza Vaccine Product Description
Fluzone High-Dose Quadrivalent,
Contains No Preservative
Presentation and Dose10 single-dose 0.7-mL prefilled syringes
Vaccine CPTa Code90662
When the Payer Requires the Outer Carton NDCb49281-0121-65
When the Payer Requires the Unit-of-Use NDC49281-0121-88
CVXc Code135
90662=Inactivated Influenza Vaccine, quadrivalent (IIV4), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use.
Influenza Vaccine Product Description
Flublok Quadrivalent,
Contains No Preservative
Presentation and Dose10 single-dose 0.5-mL prefilled syringes
Vaccine CPTa Code90682
When the Payer Requires the Outer Carton NDCb49281-0721-10
When the Payer Requires the Unit-of-Use NDC49281-0721-88
CVXc Code185
90682=Recombinant Influenza Vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use.
Influenza Vaccine Product Description
Fluzone Quadrivalent,
Contains No Preservative
Presentation and Dose10 single-dose 0.5-mL prefilled syringes
10 single-dose 0.5-mL vials
Vaccine CPTa Code90686
When the Payer Requires the Outer Carton NDCb49281-0421-50
49281-0421-10
When the Payer Requires the Unit-of-Use NDC49281-0421-88
49281-0421-58
CVXc Code150
90686=Inactivated Influenza Vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5-mL dosage, for intramuscular use.
Influenza Vaccine Product Description
Fluzone Quadrivalent
Presentation and Dosed0.25-mL dose taken from 5-mL multi-dose vial
0.5-mL dose taken from 5-mL multi-dose vial
Vaccine CPTa Code90687
(0.25-mL dose)
90688
(0.5-mL dose)
When the Payer Requires the Outer Carton NDCb49281-0635-15
49281-0635-15
When the Payer Requires the Unit-of-Use NDC49281-0635-78
49281-0635-78
CVXc Code158
90687=Inactivated Influenza Vaccine, quadrivalent (IIV4), split virus, 0.25-mL dosage, for intramuscular use.
90688=Inactivated Influenza Vaccine, quadrivalent (IIV4), split virus, 0.5-mL dosage, for intramuscular use.

Source: 2021 CPT.

Current Procedural Terminology is a registered trademark of the American Medical Association

  • a Current Procedural Terminology.
  • b NDC = National Drug Code.
  • c Code that indicates products used in vaccination.
  • d A maximum of ten doses can be withdrawn from the multi-dose vial.

Indications

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are vaccines indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone Quadrivalent is approved for use in persons 6 months of age and older. Flublok Quadrivalent is approved for use in persons 18 years of age and older. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.

Important Safety Information

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Important Safety Information

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the respective vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent may not protect all recipients.

For Fluzone Quadrivalent, in children 6 months through 35 months of age, the most common injection-site reactions were pain or tenderness, erythema, and swelling; the most common solicited systemic adverse reactions were irritability, abnormal crying, malaise, drowsiness, appetite loss, myalgia, vomiting, and fever. In children 3 years through 8 years of age, the most common injection-site reactions were pain, erythema, and swelling; the most common solicited systemic adverse reactions were myalgia, malaise, and headache. In adults 18 years and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, and fatigue.

For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent, other adverse reactions may occur.

Before administration, please see the full Prescribing Information for Fluzone Quadrivalent, Flublok Quadrivalent, or Fluzone High-Dose Quadrivalent. Also, please see complete Patient Information for Fluzone Quadrivalent or Fluzone High-Dose Quadrivalent.

Fluzone Quadrivalent Influenza Vaccine logoFlublok Quadrivalent Influenza Vaccine logoFluzone High-Dose Quadrivalent Influenza Vaccine logo

MAT-US-2019707-v2.0-08/2021